Vapor Technology Association
Sign In Sign In Sign Out Sign Out
  • About
    • About VTA
    • Priorities
    • Governance
    • Industry Marketing Standards
    • FAQ
  • Vaping Impact
  • Membership
  • Action Center
  • News

Vapor Technology Association Vapor Technology Association

Join Today Dashboard
  • About
    • About VTA
    • Priorities
    • Governance
    • Industry Marketing Standards
    • FAQ
  • Vaping Impact
  • Membership
  • Action Center
  • News

VTA Insider June 2024: VTA Testifying before congress, Update on the state of States

June 26, 2024 by Black Development

Welcome to the VTA Insider, your industry focused briefing from the Vapor Technology Association.

The VTA Insider will keep you informed of critical issues impacting the vaping industry both in Washington, DC and in the states. We will cover regulatory developments, legislation, news of note and other industry insights. VTA will also share with you our own analysis of what we as an industry need to do to grow and prosper.

Lets Dive In.


VTA testifies before Congress

On Wednesday, June 12, 2024, VTA’s Executive Director Tony Abboud had the unique opportunity to testify before the Senate Judiciary Committee in Washington, D.C. to address the myriad problems with FDA’s regulatory approach to e-cigarettes. Abboud’s testimony provided the Committee with critical scientific data shared tobacco-control scientists’ calls for a dramatic change in U.S. regulators’ approach to e-cigarettes. 

What we’re saying: Abboud’s testimony touched on three key points:

  1. FDA’s many failures and the hypocrisy of the leading health regulator authorizing 821 new cigarettes and ZERO less harmful vaping or pouch products in the last two years.
  2. The facts regarding the dramatically ameliorated youth vaping rates in the U.S. coupled with an urgent message to Congress to take up the long overdue marketing and access restrictions that VTA has been advocating for since 2018 to actually protect youth. 
  3. A renewed our call for the FDA to reverse course, authorize a wide variety of flavored e-cigarettes, make harm reduction its north star to encourage Americans who smoke to try e-cigarettes, and to enforce the Tobacco Control Act in a manner that will give tens of millions of Americans a regulated choice of less harmful flavored nicotine options and a fighting chance to get off deadly cigarettes.

Go deeper: You can catch the full hearing testimony here and read a transcript of Mr. Abboud’s opening testimony here.


UPDATED: State of the states

State of the States: Most state legislative sessions have adjourned till the fall, but there are still a few PMTA registry bills working their way through:

  • In North Carolina, PMTA registry language was snuck into H900 without any hearing or public input on the matter by big lobbyists activists. If you live / work in North Carolina, please use and share our call to action to help stop this pernicious and desperate tobacco ploy today. Your representatives need to hear from you. 
  • In Louisiana, HB 621 updating the state’s PMTA registry bill passed both houses of the state legislature and was signed by Gov. Jeff Landry. 
  • In Rhode Island. Gov. Dan McKee signed the state budget bill H 7225, converting the health department’s flavor ban to a state law. 
  • In Iowa, Gov. Kim Reynolds signed HF 2677 into law, beginning the process of creating a PMTA registry in Iowa later this fall. 

What’s next: Our fight against these bills is not over. 

  • We expect a few more states to address PMTA registration bills this year and we expect new and renewed attempts to create or expand PMTA registries next year. 
  • VTA is hard at work educating on the public health and small business damage these bills would create.

Vaping and Chevron deference

This week or next, the United States Supreme Court will release its remaining opinions of the term. The Court typically waits until final week to release to “big” decisions and there is none bigger than Loper Bright v. Raimando, the case that challenges the long standing doctrine known as Chevron deference. 

Why it matters: Chevron deference provides federal agencies with the ability to interpret and implement ambiguous statutes, so long as these interpretations are “reasonable.” For years, the doctrine has been used to uphold federal agency actions even when they seem to exceed statutory authority. 

For the vaping industry that has meant:

  • FDA’s arbitrary and capricious vaping policies have been protected by Chevron deference.
  • The vaping industry has been forced to bow to the political whims of an agency that does not want to approve less harmful non-combustible nicotine products.

What’s Next: Some legal analysts have opined that the Supreme Court could overturn or severely restrict Chevron deference and others have opined that the Court could narrowly restrict its ruling to the facts of the case. 

  • If the Court does the former, we see an avenue to force the FDA to fix their infamous “fatal flaw” approach that was designed to quickly deny marketing authorization for as many non-tobacco flavored ENDS as possible and start relying on science instead of politics in the PMTA process.

Flavored vapes for thee, but not for me

Last week, in a first, the FDA authorized menthol flavored vaping devices and finally acknowledged the enormous body of science proving flavored e-cigarettes help Americans quit smoking – not to mention FDA’s first authorization for a flavored disposable product at the highest nicotine concentration available on the market. 

  • The catch is that, to date, the only vaping products authorized are those manufactured by Big Tobacco companies. 
  • The second catch is that the week prior, FDA denied several other applications from small vaping maufacturers and wants to keep their products off the market. 

Why it matters: While the news is a tiny step in the right direction, it also reveals a more troubling pattern:

  •  FDA is acting only in self-interest to quell political pressure rather than acting in the interest of the American people.
  • Approving some but denying other substantially similar products is going to bring renewed scrutiny on how FDA is arbitrarily applying its it’s public health standard which, to date, it has refused to clearly articulate. 

The bottom line: The only vapes authorized today are all owned by the biggest cigarette companies in the world, demonstrating Brian King and the FDA’s hypocritical allegiance to those companies whose deadly cigarettes and other combustible products the FDA continues to flood the market with at a record pace (more below).

E-cigarettes are the most effective smoking cessation tool on the market and are at least 95% safer than combustible cigarettes. It is far past time for this FDA to approve a wide variety of flavored e- cigarettes and stop authorizing dangerous cigarettes.


FDA’s tawdry Big Tobacco record

Last year, VTA did a deep dive into FDA’s tobacco product approvals. The numbers were shocking then, and things have only gotten worse as our updated May 2024 report FDA is on Fire proves.

Why it matters: Until last week, FDA has refused to authorize a single premarket tobacco application for less harmful electronic nicotine delivery systems. And they have refused to authorize a single less harmful modern oral nicotine product.

What we found: In stark contrast to the more than 16,800 combustible products that FDA has authorized from 2009 to December 2023, the FDA has seen fit to authorize a paltry 45 next generation tobacco products. By category, FDA’s 45 authorizations include:

  • 2 new combustible cigarettes (low nicotine, but still combustible)
  • 4 oral tobacco mints and chews
  • 8 smokeless tobacco products (snus)
  • 8 heat-not-burn products (the IQOS device and assorted Marlboro HeatSticks)
  • 23* e-cigarettes (out of more than 20M applications filed).

*Since facts do matter, it is important to note that the often-cited list of “23” authorized e-cigarettes, only includes about 8 unique e-cigarette devices (some of which are no longer available on the market). The remainder of the list of 23 “e-cigarettes” are either replacement pods, accessories, or other products not traditionally identified as e-cigarettes.

 You can read VTA’s Report – FDA is on Fire here. 

Post script: With the new menthol authorizations, the net available vape devices on the U.S. market now hovers around 10.


The FDA enforcement trap

The latest: At last month’s Food and Drug Law Institute’s Tobacco & Nicotine Policy Conference in Washington, D.C., VTA Executive Director Tony Abboud presented thoughts on FDA’s broken enforcement policies and what that means for the future of tobacco product regulation. 

Go Deeper: Tony’s presentation highlighted some of the major problems that that FDA has created with its misguided policies in pretending that it can enforce prohibition:

  1. FDA policies have created a de facto ban on ENDS products resulting in ZERO product approvals during the current commissioner’s tenure;
  2. FDA’s enforcement of ENDS devices is not viable or efficient and is helping to create illicit markets;
  3. FDA’s enforcement policies are misplaced given that there are three times the number of youth violations for combustible tobacco products vs. vaping products;
  4. FDA’s flavor ban enforcement is driving smokers back to cigarettes

You can view a copy of Tony’s presentation here.


Worth Your Time

  • VTA Executive Director Tony Abboud joins Fox News to discuss FDA’s failures and need for flavored e-cigarettes
  • VTA Executive Director Tony Abboud quoted in Washington Post story 
  • Vape bans could lead to smoking comeback among children
  • Phillip Morris suspends Zyn online sales nationwide after DC subpoena

Stay tuned in with us for lots of new developments and make sure your friends and colleagues are signed up to receive our news and information.

Got questions? If you have any questions about the issues we have covered, have suggestions for content, or how you can support our efforts, please feel free to contact us at press@vaportechnology.org.

Filed Under: Insider, News

VTA Insider April 2024: Update on the state of the States, FDA in the Hot Seat

April 18, 2024 by Black Development

VTA Insider keeps you informed of critical issues impacting the vaping industry both in Washington, DC and in the states. We will cover regulatory developments, legislation, news of note and other industry insights. VTA will also share with you our own analysis of what we as an industry need to do to grow and prosper.

Lets Dive In.


UPDATED: State of the States

State of the States: With some state legislatures having adjourned, small business killing PMTA registry and flavor ban bills that were not stopped or amended during the regular legislative session, have reached their respective governor’s desks for signature with a mix reaction from Governors. 

  • In Virginia, Governor Youngkin substantially amended Virginia’s PMTA registry bill although he did not veto. Instead, he exercised caution by including a delayed enactment clause (meaning the most troubling provisions will not take effect until December 31, 2025) and materially changed enforcement provisions. You can read our full statement here. 
  • In Vermont, Governor Phil Scott vetoed a flavor ban bill outright and, in his veto message, delivered a refreshing perspective which highlighted the hypocrisy behind these bills when flavored cannabis and alcohol abound. 
  • In Kentucky, Governor Andy Beshear signed into law the PMTA bill, becoming only the sixth state in the country with some form of PMTA registry now on the books this year. 

What’s next: Legislation is still pending in 20 other states and VTA is hard at work educating on the public health and small business damage these bills would create. Check out VTA’s Action Center for bills needing your voice.


FDA in the hot seat

The big picture: Last week, FDA Commissioner Robert Califf was grilled before the House Oversight Committee. The issue of vaping and harm reduction came up a number of times during the three-plus hour hearing but if you were expecting any indication that FDA would come off of their unscientific approach to tobacco product regulation – you will be disappointed. 

Why it matters: Despite being forced to admit that it would be better (less harmful) for smokers to vape instead, we didn’t get any closer to a transparent explantation of where vaping fits into FDA’s smoking eradication mission. Instead, we got:

  • An incorrect explanation of how FDA is applying their “Appropriate for the Protection of Public Health (APPH) standard;
  • No explanation of how FDA will address the Reagan Udall Foundation’s critiques of the Agency allowing politics to trump science in the PMTA process;
  • No acknowledgement of FDA’s role in spreading dangerous misinformation about the risks of smoking vs. vaping.

Harm Reduction Lip Service: Remarkably, Califf raised harm reduction as the regulatory framework to be used for recreational cannabis use. But, Califf dismissively referred to “tobacco harm reduction” as an “industry term.” Clearly inconsistent on the issue, Califf paid lip service by saying “we’re all in favor of harm reduction,” but then testified that what’s found in vape “residue” is “horrifying” only to say that “it’s much less toxic in terms of all the things that cause cancer and heart disease” (i.e., cigarettes). 

By the numbers: Despite questions by Members of why CTP is authorizing 900 new cigarettes and only a handful of vape products – a finding revealed in this VTA Report – Califf incorrectly stated the public health standard as protecting against the hypothetical risk of young people getting addicted to “nicotine” and then moving to combustible products. Not only is this not the public health standard, Califf once again demonstrated FDA and CTP’s callous indifference to adult smokers.

None of this stopped FDA from stating that if CTP just had another $100 million in user fees from e-cigarette manufacturers in their budget request, they would do a better job. 

You can catch the full testimony here.


Vaping and the Supreme Court

It looking more likely that a major vaping case is likely to go before the Supreme Court in the near future. 

After the 5th Circuit Court of Appeals took apart the FDA’s bad faith denial of Triton’s PMTA, and both vacated and remanded the denials back to the agency with instructions that CTP actually review the applications, FDA has filed a filed a petition to the U.S. Supreme Court to hear the case. 

Rewind: You can read VTA’s statement on the 5th Circuit decision here. 

Why it matters: While the Supreme Court only accepts a very small percentage of the petitions filed, that the FDA as the lead regulatory agency over tobacco products has filed the petition increases the likelihood that this case will be heard. 

What’s at stake: Given the breadth of the 5th Circuit’s incisive en bancruling, the entire PMTA process being used by FDA to block vaping products from market authorization could be evaluated. Importantly, the petition would be heard only after SCOTUS issues its ruling on the Chevrondoctrine which could significantly impact how it evaluates the 5th Circuit’s stinging critique of regulatory malfeasance at FDA’s Center for Tobacco Products.


Worth Your Time

  • New research published in the Oxford Academic demonstrates that giving consumers smoking alternatives drives smoking cessation.
  • Jonathan Adler explores just how backwards FDA policy is concerning menthol cigarettes and menthol vapes.
  • Drug policy iconoclast Ethan Nadelman slams misguided nicotine prohibitionists.
  • Check out VTA’s most recent piece on how FDA is ignoring the real harm to our kids.

Stay tuned in with us for lots of new developments and make sure your friends and colleagues are signed up to receive our news and information.

Got questions? If you have any questions about the issues we have covered, have suggestions for content, or how you can support our efforts, please feel free to contact us at press@vaportechnology.org.

Filed Under: Insider, News

VTA Insider March 2024: Action across the States & Health Advocates join the fight

March 24, 2024 by Black Development Leave a Comment

VTA Insider keeps you informed of critical issues impacting the vaping industry both in Washington, DC and in the states. We will cover regulatory developments, legislation, news of note and other industry insights. VTA will also share with you our own analysis of what we as an industry need to do to grow and prosper.

Lets Dive In.


State of the States

America pulse line graphic

The Big Picture: the most pressing issue facing the vaping industry remains the dozens of PMTA registry bills that are winding their way through state legislatures in over 30 states. These bills are a blatant effort by Big Tobacco to remove safer vaping products from the market to prop up their sagging profits as Americans quit smoking in favor of safer products.

Why it Matters: The flurry of anti-vaping bills were filed on the heels of FDA’s November 2023 National Youth Tobacco Survey (NYTS). 

The 2023 NYTS survey showed plainly that there is no youth vaping crisis. It highlights:

  • A 41% drop YOY in youth vaping;
  • Only ~7.7% of teens report current use (once in the last 30 days)
  • Only ~2.5% of teens are daily users 
  • Teen vaping has dropped 61% since 2019

Given these undisputed facts, it should be increasingly difficult for elected officials and policy makers to continue to spread the lie that there is a youth vaping crisis. Unfortunately for Big Tobacco, cigarette sales are crashing so we are now facing a fight in dozens of states where legislation written by and promoted by Big Tobacco would eliminate their competition and create a monopoly for their dangerous products.

How to Fight Back: VTA is fighting back in as many states as we can but we can’t be everywhere. In the states we have lobbyists on the ground, we are running public education campaigns to explain the dangers and we are working to mobilize vape businesses that would be shuttered under these new laws. 

  • Our efforts are paying off but we need your help.

First, bills in Virginia and Florida have reached the desks of Governor Youngkin and Governor DeSantis. VTA has set up an ACTION CENTER with all the information you need to make sure the governors hear your voice.

  • In Virginia, the clock is ticking. We have less than 30 days before the General Assembly reconvenes to consider the Governor’s vetos. If you are in Virginia, please visit the VTA Action Center and urge the Governor to veto HB 1069 and SB 550.
  • In Florida, the legislative session ended on March 8th. VTA joined with the Florida Smoke Free Association urging the Governor to veto this harmful legislation.  Governor DeSantis knows that H 1007 and S 1006 are bad for public health and bad for business. The Governor has less than three weeks remaining to make his veto decisions and it is critical that he hears from you!

Health Advocates Join the Fight

Doctor looking at tablet

Strange Bedfellows Unite: When public health groups join with the vaping industry to oppose legislation, it should be a clear signal to lawmakers that these bills are bad for everybody involved. That is exactly what is happening in many of the states where we are fighting. Groups like the American Cancer Society and Clean Air For Everyone (CAFE) have registered to lobby against these bills. 

“At the end of the day, this bill will do nothing to reduce youth consumption and nor adult (use), likely,” said Threase Harms, a lobbyist for CAFE Iowa Citizens Action Network. “ … We see it as an industry bill that does nothing other than help tobacco companies increase their market share and ultimately their profits.” 

Retailers Have Problems Too: Retailers are sounding the alarm in many states that these Big Tobacco protection bills will overregulate them to the point of putting them out of business. 

What’s At Stake: Removing flavored vapes from the market will only increase cigarette sales. This is what Big Tobacco wants but it will come at a cost. For the 34 million Americans still addicted to cigarettes, without access to smoke-free alternatives, the only option for many who have tried and failed to quit will be to continue smoking. 


By The Numbers

Data in America

The negative impact of these bills goes beyond our health and wellness. Thousands of jobs are at stake and millions of dollars of economic activity supported by small businesses across the country are at risk of being eliminated. 

For Example: To demonstrate how big of a problem this is, VTA commissioned an econometric analysis of the small business market for smoke free alternatives in Florida. 

The vapor product industry is an important part of Florida’s economy. About $1.4 billion in vapor sales lead to 7,440 jobs and almost $1.3 billion in economic activity. Of these 7,440 jobs:

  • 2,471 are held by Floridians working for the 774 independent retail vape shops;
  • 369 are held by Floridians working in 13 Florida manufacturing facilities;2
  • 691 are held by Floridians working in wholesale and other retail establishments (like convenience
    stores); and
  • Nearly 3,910 full-time-equivalent jobs in Florida depend on the manufacture, distribution, and sale
    of vapor products in the state.

What’s at Stake: According to independent economists, if Governor DeSantis signs the bills, the adverse impact on the Florida economy would be nearly $1.1 billion with $845.4 million in direct sales losses.

Go deeper: You can read the full analysis here. 


The Science is Clear

The Big Picture: For smokers that want to quit, the CDC only recommends prescription nicotine replacement and counseling, despite these approaches showing little effectiveness. 

Why it matters: For years there has been a steady stream of research providing that vaping is a safer and more effective alternative for smokers looking to quit. In early February, the New England Journal of Medicine, one of the world’s most well regarded peer-reviewed journals, put the lie to the government’s recommendations.

By the Numbers: The comprehensive study tracked 1,246 smokers who wished to quit. 

  • The control group received counseling and the government approved nicotine replacement therapy. 
  • The other group was also permitted to also try to quit using e-cigarettes. 
  • The participants who were given the option to vape were able to quit at rates that were 21% higher than the control group.

What they’re saying: In an editorial accompanying the study, Professor Nancy Rigotti, Professor of Medicine at Harvard Medical School indicated that: 

“It is now time for the medical community to acknowledge this progress and add e-cigarettes to the smoking cessation toolkit… U.S. public health agencies and professional medical societies should reconsider their cautious positions on e-cigarettes for smoking cessation. The evidence has brought e-cigarettes to the tipping point. The burden of tobacco-related disease is too big for potential solutions such as e-cigarettes to be ignored.”

It is time for scientists, not bureaucrats at FDA and CDC to lead the public health discussion.


Worth Your Time

Clock on medicine pill
  • Investors cut guidance on Big Tobacco stocks as vaping cuts into profits. This is an October 2023 story, but it tells you everything you need to know about why tobacco companies are pushing these PMTA registry bills across the country.
  • Restrictive anti-vaping policies are fueling a dangerous black market in other countries.  
  • Consumer groups are sounding the alarm against state PMTA registry bills.
  • When doctors are the source of public health misinformation.

Stay tuned in with us for lots of new developments and make sure your friends and colleagues are signed up to receive our news and information.

Got questions? If you have any questions about the issues we have covered, have suggestions for content, or how you can support our efforts, please feel free to contact us at press@vaportechnology.org.

Filed Under: Insider, News

VTA Insider June 2023: Fentanyl Threat & FDA Over Regulations

July 12, 2023 by Ethan D'Souza Leave a Comment

VTA Insider keeps you informed of critical issues impacting the nicotine products industry both in Washington, DC and in the states. We will cover regulatory developments, legislation, news of note and other industry insights. VTA will also share our analysis of what we as an industry need to do to grow and prosper.

Let’s Dive In.


Beware of the Fentanyl False Flag

Beware of the Fentanyl False Flag

What’s New: Recently, VTA’s Executive Director Tony Abboud presented a stark warning to the industry at the Next Generation Nicotine Delivery Conference in Miami, Florida. The newest and greatest threat to the availability of less harmful nicotine vaping products in the U.S. is an ongoing orchestrated public affairs campaign to the unsubstantiated claims that illicit Chinese supplied vaping products are being laced with products such as fentanyl. 

Why it matters: This will have ramifications for the entire industry and the millions of consumers because it jeopardizes all vaping products. 

The facts: If, as asserted, millions of “illegal flavored disposables” are being imported into the U.S. with fentanyl, where’s the outbreak? The made up fentanyl narrative has all the markings of EVALI:

  • Hospitalizations and illnesses involving young people using THC vapes.
  • Products clearly adulterated by unscrupulous drug dealers.
  • Headlines are hyped and conflate all vaping products.
  • Direct calls for eliminating flavored nicotine vaping.
  • Regulators and legislators are feeding the misleading narrative.

What it means: The fentanyl narrative threatens all nicotine vaping because nearly every vaping product is manufactured in China. If we allow this fiction to take root – it will scare consumers away from vaping and back to smoking and create an opening for FDA to deny all PMTAs.

The damage will NOT be limited to disposables. The campaign is as anti-flavor as it is anti-disposable.The geopolitical narrative is so hyped it will taint all vape devices since they ALL are made in China.

Bottom line: the vaping industry will not get three strikes. The industry must coalesce around a response on the level of the actions we took to stop the ill-conceived flavor ban response to the EVALI crisis. A copy of VTA’s presentation is available here.


FDA’s Poisonous Pantomime

FDA’s Poisonous Pantomime
FDA Whitewashes Vaping Data Once Again.

The big picture: At the end of June, the FDA staged yet another “retail blitz” to manufacture a vaping crisis that does not exist. If this sounds vaguely familiar it’s because it’s the same playbook that FDA has used time and again. 

  • What’s different this time: FDA paired their blitz announcement with two CDC reports that traffic in dangerous misinformation and blatantly misrepresent the real trends in youth vaping. 
  • The first study FDA presents includes aggregated retail data (not youth usage) that show vapes sales are up and by implication – youth usage. This is not the case. CDC’s own National Youth Tobacco Survey has shown the dramatic reduction in youth e-cigarette use. As smokers use ENDS products to quit cigarettes – we should expect to see replacement trends at the retail level. 
  • The second study FDA presents attempts to portray an increase in calls to poison control centers related to vaping as sign that a crisis as at our doorstep. To do that, FDA presents this data out of context.
  • Go deeper: If we told you that there were 6,074 cases for children under the age of five related to vaping you might be concerned. But what if you also knew that:
    • There were 96,000 cases involving cosmetics
    • There were 94,000 cases involving household cleaners
    • There were 72,000 cases involving prescription drugs
    • There were 6,180 cases involving THC (cannabis)

The bottom line: 34 million adults are addicted to cigarettes – the only product which when used as intended will kill you. By selectively targeting vaping under the false pretense of a youth cris, FDA is working overtime to eliminate effective harm reduction options for adults and ensuring the only option for many will be to continue smoking.


VTA Files SCOTUS Brief Supporting Avail Vapor’s 4th Circuit Appeal

VTA Files SCOTUS Brief Supporting
VTA at the Supreme Court

The big picture: On June 14, 2023, the Vapor Technology Association (VTA) filed an amicus curiae brief  with the Supreme Court of the United States in the case Avail Vapor, LLC, et al. v. US Food & Drug Administration. VTA’s petition seeks Supreme Court review of the Marketing Denial Orders issued to petitioners in connection with their open-system flavored vaping products.

Go deeper: World’s leading tobacco and nicotine researchers have undermined the scientific underpinnings of the FDA’s decision-making rationale. Review by the Court is important not to re-examine the science (which courts will not do), but to evaluate the propriety of the highly questionable process. 

By the numbers: The independent vapor industry comprises more than 10,000 companies across the U.S. The industry is responsible for generating more than 130,000 jobs. FDA’s removal of all flavored vaping products from the market would lead to the shutdown of close to 10,000 businesses, causing the loss of 99,158 full-time equivalent jobs.

Why it matters: One week after the Fourth Circuit’s decision upholding the MDOs, an Independent Tobacco Expert Panel released its report on FDA’s Center for Tobacco Products which revealed serious regulatory failings of the agency, including those specifically raised by Petitioners in the Supreme Court Petition.


Worth your time

Worth your time
News and information you can use.
  • A recent study in the American Journal of Medicine finds that among individuals attempting to quit smoking, nicotine e-cigarettes are more efficacious than conventional nicotine replacement or behavioral smoking cessation therapies, and may prove beneficial in reducing smoking-related health risks.
  • Reason Magazine recently published a piece highlighting that since the Food and Drug Administration began regulating ENDS as “tobacco products,” public understanding of the relative risks of various tobacco products has declined.

Stay tuned in with us for lots of new developments and make sure your friends and colleagues are signed up to receive our news and information.

Got questions? If you have any questions about the issues we have covered, have suggestions for content, or how you can support our efforts, please feel free to contact us at press@vaportechnology.org.

Filed Under: Insider, News

VTA Insider May 2023: LBGTQ & Nicotine Products

May 30, 2023 by Black Development Leave a Comment

VTA Insider keeps you informed of critical issues impacting the nicotine products industry both in Washington, DC and in the states. We will cover regulatory developments, legislation, news of note and other industry insights. VTA will also share our analysis of what we as an industry need to do to grow and prosper.

Let’s Dive In.


A heavy lift in DC

E-Cig Summit

The big picture: The E-Cig Summit and the Food and Drug Law Institute convened in Washington, D.C. There is too much to detail in this newsletter but a few key big-picture takeaways:

Science is clear: Scientists from around the world convened to discuss the continuing growing body of the science behind the importance of vaping and nicotine alternatives to smoking cigarettes. In study after study presented, the scientists presented unflinching perspectives on everything from data to policy. 

The Consensus: FDA is broken and is failing in delivering an effective harm reduction message. Vaping can be a huge benefit to public health and there is ample evidence supporting the potential of vaping to reduce smoking’s toll. Making it harder for adults to access vapor products makes it harder for them quit and ensures that they engage in the riskiest behavior, (smoking) longer.

Why it matters: Litigation is now effectively driving health policy. FDA had a plan to review the large number of PMTAs received and to streamline its reviews in a scientifically defensible matter for flavored ENDS. FDA had announced its plans, priorities and processes in June 2021. 

  • Then, all that changed with the direct interference from a former Acting Commissioner who forced the creation of the “fatal flaw” memorandum which was used to en masse deny all flavored vaping products.
  • This and other interference with scientific decisions was called out by scientists inside & outside FDA’s Center for Tobacco Products.
  • Given FDA’s actions, companies had no option but to litigate.

FDA enforcement needs to be focused on the bad actors, i.e., those companies which have completely ignored FDA’s regulations. While Director Brian King proudly spoke about the pace of PMTA denials (99% of all vaping products) he acknowledged the difficulty with enforcement. No surprise here since bans cannot be enforced. But, as was highlighted in the Reagan-Udall report, FDA has taken little action against companies that chose never to even apply through the PMTA process.


Misinformation for the masses

Data courtesy of Clive Bates from Counterfactual
Data courtesy of Clive Bates from Counterfactual

At the E-Cig summit last week, our friend Clive Bates of Counterfactual gave an excellent presentation focused on how the U.S. should be rethinking tobacco and nicotine regulation. The entire presentation is worth a read but the chart above is a perfect encapsulation of the problem. 

The public is being fed misinformation concerning the relative health risks of smoking vs. vaping and the problem is getting worse. People are now more likely to believe that vaping is as dangerous as smoking than they were ten years ago. 

FDA officials acknowledged the problem of misinformation during the Q&A segment at the E-Cig Summit and committed to developing a public affairs campaign targeted at adults. These type of campaigns take months to develop so don’t expect anything dramatic anytime soon. 

Doubling Down on Youth.  In the same talk, however, CTP Director Brian King, who again acknowledged the dramatic decline in youth vaping, doubled down on youth experiementation. He said there is no acceptable level of youth vaping usage, foretelling what will continue to dictate FDA’s continued vaping product denials. 

The bottom line: Quitting smoking is hard. Only 10% of adults who try to quit will ultimately succeed. FDA needs to expand the understanding of the dramatically less risky alternatives to smoking for tens of millions of adults who are addicted. Of course vaping is not free from risk and there are trade-offs but those tradeoffs should be made explicit so that we can reduce death and disease by giving people the information to de-risk their behavior.

  • But, Director King went on to say that there was a difference between enforcement discretion and enforcement prioritization.
  • King promised promised a formal letter soon from CTP in response to VTA’s questions to clarify CTP’s position.

Advancing harm reduction equity

fda vapor regulations
FDA Must First Practice Harm Reduction Equity to Achieve Health Equity

The big picture: CTP Director Brian King has made the concept of “health equity” as it relates to tobacco product regulation a centerpiece of his plan. King characterized FDA’s focus on health equity in the following way:

  • “We have a tremendous opportunity to prioritize health equity and create meaningful change for populations that have been disproportionately affected by tobacco use.”
  • Director King also created the first “health equity” leadership position inside CTP.

By the numbers: Smoking remains the number one health risk to adults in the United States. Approximately 34 million adults are still addicted to cigarettes – the only product which when used as intended will kill you. In the LBGTQ communities – the problem is worse. LGBTQ people out-smoke the general population by 68%. This high rate of LGBTQ smoking is a current and ongoing health crisis. In fact, according to the NIH, smoking related deaths are on track to surpass HIV/AIDS as a cause of death among gay men.

Why it matters: CTP is promoting health inequity and would be better served to focus on vaping as a tool to promote “harm reduction equity” which would have more immediate benefits and potentially immeasurable benefits for historically marginalized communities. 

The bottom line: The FDA and its Center for Tobacco Products (CTP) is charged with protecting all Americans from tobacco-related disease and death. 

  • This means the FDA must do everything to help people move off combustible tobacco and toward lower risk alternatives. FDA’s backward approach to harm reduction means that it is easier to get a new deadly cigarette product approved than an e-cigarette alternative.
  • And the fact that the FDA has declared more than 99% of vaping products “illegal” means that the only choice left remaining will be deadly cigarettes.

Harm Reduction Equity: Conversely, a focus on harm reduction equity means telling the communities that are disproportionately impacted by smoking related death and disease the truth – that vaping while not risk free is less risky than smoking. Given the unequal burden the LGBTQ community and other populations disproportionately affected by smoking (such as the African-American community, those of lower incomes, those afflicted with mental health issues) bear for cancer and other health risks associated with smoking, limiting adult choices and access to lower risk products will only serve to expand health inequities in our society.


The real story on combustibles

vape laws
The Smoking Gun

FDA has a responsibility to create a marketplace that allows the most innovative and safe products to emerge so that adults have access to them. With all the news about the product denials for flavored vaping products, you might be surprised to learn that the FDA has approved for sale more than 1,200 combustible products including nearly 900 new cigarettes!

FDA Approvals of Combustible Tobacco Products 2018 –2022

FDA Approvals of Combustible Tobacco Products
Source: Vapor Technology Association analysis of FDA Tobacco Products Marketing Orders, last accessed 3/16/23; content current as of 2/23/23.

FDA Commissioner Robert Califf recently said in a March 6, 2023 Wall Street Journal interview, “There aren’t many people who argue in favor of combustible tobacco … Well, I mean, we always start from the presumption that combustible tobacco is the most dangerous part of this. And we need to get rid of that as much as we possibly can. It’s written into the mission of the FDA.”

There aren’t many people who would argue with that. So why is the FDA under his leadership approving so many of combustible products? You can check out the full VTA analysis of FDA product approval data here. 

FDA’s continued refusal to accept known scientific truths about vaping and modern oral nicotine will only ensure that cigarettes remain dominant in the U.S. 


Worth your time

Leading Tobacco Control Experts
News and information you can use.

Leading Tobacco-Control Experts call on FDA to change – and fast.

  • some of the world’s leading tobacco-control scientists and public health experts wrote to FDA Commissioner Califf calling on him and the FDA to rethink its current posture.
  • The group focused on the hyper-critical findings of the Reagan-Udall Foundation’s review of CTP and made specific recommendations for changing the way CTP handles tobacco and vaping regulations.

Juul Whitepaper:  Juul Labs Inc. has published  “The Real-World Impact of ENDS for Adult Smokers: Tobacco Harm Reduction Through Real-World Data and Evidence.” We encourage you to read it here. 

Two main requirements of effective harm reduction: (1) that the products are much less harmful than cigarettes, and (2) that these products displace smoking at the population level. 

No doubt the whitepaper it will be panned because of the source but “risk-proportionate regulation” is related to FDA’s “continuum of risk” concept. We have to keep pushing to embed this harm reduction priority as our public health strategy.


Stay tuned in with us for lots of new developments and make sure your friends and colleagues are signed up to receive our news and information.

Got questions? If you have any questions about the issues we have covered, have suggestions for content, or how you can support our efforts, please feel free to contact us at press@vaportechnology.org.

Filed Under: Insider, News

VTA Insider Jan 2023 – Smoking vs Vaping, Vaping Info and Regulations.

February 6, 2023 by Black Development Leave a Comment

VTA Insider keeps you informed of critical issues impacting the nicotine products industry both in Washington, DC and in the states. We will cover regulatory developments, legislation, news of note and other industry insights. VTA will also share our analysis of what we as an industry need to do to grow and prosper.

Let’s Dive In.


1 big thing: VTA meets with King…again

Reagan-Udall Foundation Reports Serious Problems at FDA Tobacco

The big picture: Kicking off the New Year, on January 10, 2023, VTA leadership and select board members met with CTP Director Brian King and other leadership at the Center for Tobacco Products (CTP) to discuss top agenda items for the year. This was the second meeting that VTA has had with King in the last four months.

Top takeaway: Director King acknowledged the fact that youth e-cigarette use continues to decline but was ambiguous on the reshaping of CTP policy regarding adults, noting they are considering how to address the Reagan-Udall recommendations and looking to engage more with stakeholders.

Remember, Reagan-Udall told CTP to: “resolve how to weigh the public health benefits of adults who use ENDS that will quit smoking combustible tobacco products against the potential public health harms to youth who use e-cigarettes.”

The rest of the agenda: VTA focused on the most pressing issues impacting our members and the industry including:

  • Implementing Reagan-Udall Recommendations
  • Enforcement Discretion for Non-Tobacco Nicotine
  • Need for an Objective APPH Test
  • Industry Stakeholder Engagement

VTA presses CTP on clarifying enforcement discretion policy

VTA presses CTP on clarifying enforcement discretion policy

The “million dollar” question: CTP has historically allowed all tobacco products with pending PMTAs to remain on the market, subject to FDA’s enforcement discretion, but in the past few months has been making confusing statements particularly with respect to non-tobacco nicotine products. Following up on VTA correspondence from early November 2022, we asked Director King: “Has CTP had changed its well-established enforcement discretion policy for non-tobacco nicotine products only?”

What we said: It’s extremely important that we get clarity on this question so all market participants understand CTP’s position and so that companies are not able to misrepresent CTP’s position for their own benefit.

  • For years, CTP has used enforcement discretion to allow all tobacco products with pending PMTAs to remain on the market and that policy should be consistently applied to tobacco and non-tobacco nicotine products alike.
  • Some companies have been attempting to confuse retailers and dissuade them from carrying synthetic nicotine products by claiming that CTP uses enforcement discretion only for tobacco-dervied nicotine products and not for synthetic nicotine products.
  • Nothing in the new law limited CTP’s enforcement discretion – in fact, CTP has been exercising that discretion – and CTP would never unilaterally limit its own discretion.

What they’re saying: During the meeting Director King indicated that had been no policy change with respect to CTP’s use of enforcement discretion.

  • But, Director King went on to say that there was a difference between enforcement discretion and enforcement prioritization.
  • King promised promised a formal letter soon from CTP in response to VTA’s questions to clarify CTP’s position.

King to VTA: FDA has no enforcement discretion policy for TDN or NTN products

FDA has no enforcement discretion policy for TDN or NTN products

The big picture: CTP has exercised enforcement discretion for years. CTP has asked courts not to limit its enforcement discretion. CTP has explained its actions or inactions based on enforcement discretion.

Why it matters: CTP has consistently used its enforcement discretion to allow products under PMTA review to remain on the market pending a final PMTA determination. Manufacturers, distributors and retailers have relied on CTP’s statements to continue selling less harmful vaping products. Heck, CTP has been criticized by anti-harm reduction forces for using enforcment discretion.

About Face: On February 2, 2023, VTA received the formal response letter promised by Director King in which he clarified that:

  • TDN products are not being treated differently than NTN products.
  • CTP has not been using enforcement discretion for tobacco-derived nicotine products or synthetic nicotine products.
  • In fact, CTP does not even have a policy on enforcement discretion.
  • All products, regardless of whether they include tobacco-derived nicotine or synthetic nicotine, are illegal and cannot be sold until their PMTAs have been authorized.

Go deeper: While CTP acknowledged that FDA originally said it would use enforcement discretion, that changed. Here is how Director King recasts what CTP has been doing:

“Accordingly, your letter’s assertion that FDA is “us[ing] its enforcement discretion to allow . . .products to remain on the market” while they undergo review is not correct. On the contrary, as the guidance reiterates, all illegally marketed TDN e-cigarette products are subject to FDA enforcement. The same principle applies to NTN products; specifically, all illegally marketed NTN products are subject to enforcement.”

“FDA cannot affirmatively allow or permit the unlawful marketing of tobacco products, including TDN and NTN e-cigarette products; as the above statements reflect, all illegally marketed products are subject to FDA enforcement, such a seizure, civil money penalty, or injunction. Moreover, FDA has not adopted a broad policy of enforcement discretion with respect to TDN or NTN e-cigarette products that lack the required premarket authorization.”

Why Now?

  • Sure, VTA has been presssing CTP on clarifying the question of enforcement discretion for months.
  • But, we can’t help noting that CTP’s 2-page letter (three months in the making) was received just one day after Sen. Richard Durbin (D-IL) and other Senators issued another press release and sent a letter to HHS Secretary Xavier Becerra blasting CTP for its, yes, “exercise [of] enforcement discretion,” and demanding “This enforcement discretion should have ended years ago. It must end today.”
  • At least now we know that FDA is not using enforement discretion for any nicotine-containing product.

VTA to FDA on Reagan-Udall: Need to Pull It Together, Together

FDA's lack of strategic planning within the CTP

One big thing: The Reagan-Udall report raised a number of critical issues regarding CTP’s handling of tobacco regulation that demand immediate attention and immediate industry engagement. VTA learned that CTP will formally respond to the Reagan-Udall report in mid – February. With that in mind, in our January conversation with Director King, VTA highlighted the Reagan-Udall recommendations that mirrored VTA’s own recommendations:

  • CTP needs a strategy: Reagan-Udall said that CTP has no strategic plan and “must create [a strategic plan] that identifies the CTP’s strategic objectives and plots an operational roadmap of the steps CTP will take over the next five years to achieve those objectives.” VTA strongly supports this recommendation and noted its agreement with Reagan-Udall that the path to resolving many of the CTP’s self inflicted problems starts with establishing the scientific and policy framework for tobacco harm reduction.
  • CTP needs to establish what is APPH: Reagan-Udall made clear that CTP must “explain how FDA is interpreting the [appropriate for the protection of public health] APPH standard” and how it is weighing “the public health benefits of the percentage of adults who use ENDS that will completely quit smoking … against the potential public health harms [to] youth.” VTA noted that APPH evaluations were being subjectively decided in conflict with the science. VTA offered to work with CTP on an objective process for ensuring that APPH decisions are made without political or outside interference.
  • CTP must advocate clearly for harm reduction: Reagan-Udall noted that “CTP lacks consistent implementation of its own policies, particularly with respect to harm reduction” which undercuts CTP’s mission. CTP has acknowledged the continuum of risk but has no clear policy or strategy on harm reduction. VTA emphasized the need for a clear APPH standard and clear messaging from FDA on harm reduction.
  • CTP must be transparent: VTA has consistently raised concerns regarding the opaque operations of the CTP. Reagan-Udall’s review highlights a shifting decision-making process, lack of clarity on responsibilities, and impact of extreme external pressures. Transparency in decision making is as imporatnt as transparency and engagement in the policy process. We urged CTP to create opportunities for communication outside of the rule making process and recognize that companies which are spending millions of dollars are acting in good faith and need to be engaged early.

What’s next: Based on Director King’s statements and promises, we should expect a much higher degree of stakeholder engagement, including VTA and other industry engagement, with CTP on the critical issues raised by Reagan-Udall. However, it is unclear how FDA/CTP will choose to address Reagan-Udall’s serious criticisms. It is equally unclear whether CTP will tackle the problems with enough force to change CTP’s trajectory away from propping up cigarettes and toward replacing them with less harmful vaping and modern oral products.


Progress in The Courts

Wages & White Lion v. FDA

The big picture: FDA CTP is embroiled in litigation throughtout the country which is testing whether FDA’s “fatal flaw” approach to PMTAs and its implementation of post-application testing prerequisites violate the law. Those cases, pending in various federal appellate courts, could end up in conflict thus paving the way for SCOTUS review.

One important case: Wages & White Lion v. FDA, is pending in the 5th Circuit. There, the petitionr originally secured the “suprise switcheroo” opinion which heavily criticized the FDA for changing the application requirements after the fact and imposed a preliminary injunction barring the FDA from enforcing its MDO against Wages & White Lion. However, in a split-decision (2-1), the final panel agreed with the FDA and denied the appeal.

5th Circuit Rehearing: Wages & White Lion asked all 9 judges of the 5th Circuit to review the case and that request was granted so the full 5th Circuit panel will now make the court’s final decision. VTA filed an amicus brief in support of the request for a rehearing en banc, provinding the court with the findings of its experts’ analysis of the severe economic ramifications of the FDA’s flavor ban.


FDA’s Illogical VUSE on Menthol

FDA’s Illogical VUSE on Menthol

The big picture: Last month, FDA issued market denial orders for two VUSE menthol PMTAs filed by R.J. Reynolds. You can read FDA’s statement here. This after FDA denied LOGIC’s menthol vape PMTAs, filed by JTI, last year. The tobacco giant quickly obtained an injunction from a federal court to bar enforcement of the FDA’s decisions.

Why it matters: It is safe to say that we have entered the unfortunate reality where FDA is intent on treating menthol products in the same dismissive manner in which it has treated all other flavored vaping products to date. It appears that no amount of science will be sufficient for FDA leadership and that in the absence of menthol vapes, former smokers will become smokers again.


Stay tuned in with us for lots of new developments and make sure your friends and colleagues are signed up to receive our news and information.

Got questions? If you have any questions about the issues we have covered, have suggestions for content, or how you can support our efforts, please feel free to contact us at press@vaportechnology.org.

Filed Under: Insider, News

VTA Insider December 2022 – FDA Tobacco Regulations

December 23, 2022 by Cheyenne Kamran Leave a Comment

Welcome to the December edition of the VTA Insider, your industry focused briefing from the Vapor Technology Association.

VTA Insider keeps you informed of critical issues impacting the nicotine products industry both in Washington, DC and in the states. We will cover regulatory developments, legislation, news of note and other industry insights. VTA will also share our analysis of what we as an industry need to do to grow and prosper.

Let’s Dive In.


Reagan-Udall Issues Critical Report on FDA Tobacco

Reagan-Udall Issues Critical Report on FDA Tobacco

The big picture: Last July, FDA Commissioner Robert Califf called for an indpendent review of the FDA’s heavily criticized Center for Tobacco Products (CTP) by the Reagan-Udall Foundation (RUF). The RUF report, released last week, painted a troubled picture of a CTP’s culture, inconsistent and opaque rules and standards, and political interference with what should be scientific decisions.

What the experts found: RUF’s independent panel of tobacco experts found:

  • CTP has no strategic plan and must create one that identifies the Center’s strategic objectives and plots an operational roadmap to achieve them.
  • CTP has not clearly articulated what is required to meet the appropriateness for the protection of public health (APPH) standard or how it is applying the APPH standard.
  • CTP struggles to function as a regulator due to some of its own policy choices.
  • CTP faces significant challenges in clearing policies through the career and political infrastructure.
  • CTP lacks consistent implementation of its own policies, particularly with respect to harm reduction.

RUF Recommendations: Some of the most important recommendations of the independent tobacco expert panel:

  • “The Panel strongly recommends that the center invests the time – now – in … thinking strategically about where it is deficient, where it needs to be in the future, and how best to get to that future.”
  • “The path to resolving many of the Center’s current challengesstarts with establishing the scientific and policy framework to make clear and timely product decisions.”
  • “The plan must … explain how FDA is interpreting the APPH standard.”
  • “CTP has a responsibility to clearly identify application requirements.”
  • “CTP must resolve how to weigh the public health benefits of adults who use ENDS that will quit smoking combustible tobacco products against the potential public health harms to youth who use e-cigarettes.”

Why it matters: Using the addled prcess described by RUF, CTP hasrejected the overwhelming majority of applications for millions of less-harmful vaping products and has done so without being able to articulate how it is balancing the public health standard.

Keeping score: 600 – 8 – 0 – 0 – 0 – 0

  • 600 = the # of combustible tobacco products, including 250 new cigarettes, authorized for sale.
  • 8 = the # of less harmful tobacco-flavored e-cigarettes authorized.
  • 0 = the # of less harmful menthol-flavored e-cigarettes authorized.
  • 0 = the # of less harmful other-flavored e-cigarettes authorized.
  • 0 = the # of less harmful open-system devices authorized.
  • 0 = the # of less harmful nicotine pouch products authorized.

Our thought bubble: “The FDA Commissioner should instruct CTP to stand down on issuing any further denials of less harmful nicotine alternative product applications until CTP has been able to review and implement the safeguards and recommendations made by the Reagan-Udall Foundation, and VTA stands ready to assist FDA and CTP by providing the necessary stakeholder input that the Foundation also said was necessary,” said VTA’s Executive Director.

Read VTA’s full statement on the RUF Report, VTA’s oral testimony to RUF, the summary of VTA’s recommendations and its full written submission to RUF.

Watch VTA’s Executive Director discuss the RUF report on Regulator Watch.


Where’s the logic?

FDA Vapor Regulations

The big picture: On October 26, 2022, FDA denied Logic Technology Development, LLC’s (LOGIC) menthol-ENDS PMTA applications claiming that LOGIC failed to prove that its menthol products were appropriate for the protection of public health (APPH). But, in documents made public recently, LOGIC revealed that CTP’s Office of Science changed its standards for reviewing menthol-ENDS PMTAs aftereffectively being told to do so by the CTP Center Director’s office.

  • In a memo written by the head of the Office of Science, it was disclsoed that the scientists initially decided to authorizeLOGIC’s menthol-ENDS products back “in the latter half of 2021” after taking into account all factors including potential attraction to youth.
  • But, after the Center Director’s office “shared [its] views,” the Office of Science changed its approach and recommendation to deny LOGIC’s menthol PMTAs.

Why it matters: It appears that CTP is applying the same flawed youth-oriented decision making process for evaluating menthol-flavored vaping products as it did other-flavored vaping products. In other words, anypotential youth use outweighs LOGIC’s studies demonstrating little to no youth uptake and significant adult smoking cessation.

What we’re saying: CTP’s decision was made during using a process which the Reagan-Udall Foundation was highly critical of due to CTP’s lack of transparency on the balancing test and what appear to be scientific decisions getting overriden by policymakers at the agency. VTAshared copies of the internal FDA memos with the Reagan-Udall Foundation before it issued its report. 

What’s next: LOGIC, having already filed suit, has its case on what appears to be a fast track so we hope to see a court decision soon.


Worth your time…

 E-Cigarette News

Must-see webinar on age-gating. Missed the recent webinar Protecting your Brand, Products, & Consumers: Age-Gating and Supply Chain Security? Watch this free 60-minute webinar moderated by Dr. Jessica Zdinak, with Dave DeJean and Eric Hawk. Use the passcode: =rk0V3k0

Attorney General Tom Miller and leading tobacco-control scientists published a must-read editorial in Addiction entitled United States Public Health Officials Need to Correct E-cigarette Health Misinformation

“Health misinformation is harmful as it can cause confusion and sow mistrust regarding the adoption of public health recommendations and policies. We provide examples of e-cigarette misinformation promoted by the United States public health officials, which have persisted despite new data challenging the validity of the original assertions.”

VTA Executive Director Tony Abboud speaks to Regulator Watchabout a number of regulatory updates. Abboud discusses litigation, flavored ENDS appeals, and Supreme Court flavor cases and much more.


Happy Holidays To All

Happy Holidays

We at VTA are wishing everyone a safe (warm!) and happy holidays as we look forward to a new year filled with change and prosperity!

Stay tuned in with us for lots of new developments in the coming year and make sure your friends and colleagues are signed up to receive our news and information..

Filed Under: Insider, News

VTA Insider November 2022 – FDA Tobacco Laws and Regulations

November 25, 2022 by Tony Leave a Comment

Welcome to the inaugural edition of the VTA Insider, your industry focused briefing from the Vapor Technology Association.

The VTA Insider will keep you informed of critical issues impacting the nicotine products industry both in Washington, DC and in the states. We will cover regulatory developments, legislation, news of note and other industry insights. VTA will also share our analysis of what we as an industry need to do to grow and prosper.

Let’s Dive In.

1 big thing: GOP takes the House

The big picture: Although vote counting continues in some races, Republicans have officially picked up enough seats to take majority control in the House. But, with Republican control of the House floor, committees and the policy agenda, split party rule returns to Washington D.C. While this is often a recipe for legislative gridlock – split control can help focus leaders of both parties on solving problems that they were not motivated to address before. 

Why it matters: The vast oversight and investigation authority the new House majority will have will put a number of federal agencies and programs under the microscope. GOP leaders already have articulated a large number of issues on which they plan to conduct oversight and investigations: everything from the Afghanistan withdrawal, to COVID, to possible impeachment.

What’s next: VTA’s lobbying and public affairs teams will share their insights on what happened in the recent election and what we can expect to change in Congres in 2023 during VTA’s 2022 Post-Election Round Up webinar on November 30, 2022. Register for the webinar today.

Our thought bubble: VTA has spent the past year working on a bi-partisan strategy that would take serious strides in addressing both youth and adult access to flavored vaping products and the closely divided Congress will necessitate a bi-partisan approach. Also, VTA will be working with the new Congress to ensure they it understands the problems that FDA’s Center for Tobacco Products has had historically.


FDA under the microscope?

FDA Commissioner Califf calls for an independent review

The big picture: This summer, FDA Commissioner Califf called for an independent review, by the Reagan – Udall Foundation (RUF), of FDA’s Center for Tobacco Products (CTP) and its handling of tobacco products. RUF was created by Congress “to advance the mission of the FDA…” and it is now taking a deep dive into the operations of the CTP.

Why it matters: The issues at CTP which VTA has been working to resolve for a number of years, particularly how CTP has handled e-cigarette PMTAs, are beginning to receive long overdue attention. All parties were able to submit comments to RUF and, suprisingly, some of the most troubling feedback has come from FDA staff. 

What they’re saying: Some CTP staff have been highly critical of how CTP has handled e-cigarettes and they lay bare some of the worst fears about what has been going on inside CTP. Here’s a sample of some of the more concerning comments from CTP staff:

  • “Politics are being permitted to drive the science and even limit or alter science-based decisions.”
  • “In cases where reviews are finished and scientific decisions are made they are also overruled by political agendas and pushed to change decisions.”
  • “…leadership pushes a “gotta get em” mentality onto staff, which is unsupportive of a reviewer’s fundamental duty to provide an unbiased review using the best available science.”
  • “FDA needs to use its authority … to refuse import of all disposable tobacco ENDS products that lack pre-market authorization. This would virtually eliminate youth access to disposables and address unauthorized, unsafe, and in many cases counterfeit disposable products.”

Go deeper: VTA was invited to present comments on needed changes to RUF’s independent tobacco expert panel in October and offered a number of specific recommendations, most notably stating the need for CTP to insulate itself from politics and external pressures in reviewing PMTAs and to “unapologetically” follow the science.

What’s next: RUF will complete its review and will publish a report with recommendations in December of this year.


Defending flavored vapes

Flavored Vapes

The big picture: On Nov. 8, 2022, voters in California passed a ballot initiative (Proposition 31) upholding a 2020 law banning the sale of most flavored tobacco products. The next day, R.J. Reynolds (RJR), filed a federal lawsuit challenging California’s ban. On November 14, VTA filed an amicus brief with SCOTUS in support of a similar RJR case arguing that federal law preempts local and state flavor bans. These cases could have a big impact on local/state flavor bans across the country.

VTA argued that Supreme Court review is critical for economic and public health reasons:

By the numbers: The independent vapor industry comprises more than 10,000 companies across the U.S. VTA’s economists found that the independent vapor industry is responsible for generating more than 130,000 jobs. In new economic impact report VTA commissioned, experts found that a flavor ban would cause the loss of more than:

  • 99,000 jobs;
  • $5 billion in wages and benefits; and
  • $16 billion in lost economic output for the U.S.

What experts are saying: VTA also argued that leading tobacco-control scientists have challenged banning flavored e-cigarettes and have warned that decreasing availability of flavored vaping products harms the ability of adult smokers to quit smoking. Instead of blanket bans, these tobacco-control scientists endorse alternative time, place and manner restrictions for the sale of flavored vaping products.

The bottom line to SCOTUS: Permitting local and state governments to implement unscientific sales bans which directly interfere with the fundamental purpose of the TCA and which would overrule FDA’s decisions that a product is appropriate for the protection of public health, is not only unlawful, but is dangerous from a public health perspective.

What’s next: VTA will keep you updated as the litigation proceeds. 


Worth your time…

E-Cigarette News

What we’re saying

VTA’s Executive Director at the ENDS US 2022 conference speaking on “PMTA: Lessons Learned.” Watch the video below.

In an excellent piece by Marc Gunter in Filter Mag entitled Can the Tobacco Control Debate Find Common Ground?:

“Some industry leaders are willing to accept regulation. Tony Abboud, the Executive Director of the Vapor Technology Association, which represents vape shops, says his group would accept reasonable restrictions on where e-cigarettes can be sold and how they can be marketed. Abboud also said: ‘We’ll sit down with anybody.’”

Worth the read

  • California’s Vaping Flavor Ban Could Be Lethal
  • New Study Shows that Vaping Helps Adult Smoker Quit
  • FDA and CDC Are Misleading the Public About Youth Vaping Data

Stay tuned in with us for lots of new developments and make sure your friends and colleagues are signed up to receive our news and information.

Got questions? If you have any questions about the issues we have covered, have suggestions for content, or how you can support our efforts, please feel free to contact us at press@vaportechnology.org.

Filed Under: Insider, News

Follow Us

  • Twitter
  • YouTube
  • Facebook

Copyright © 2024 Vapor Technology Association.
All Rights Reserved.

Privacy Policy |
Terms Of Use

Created by Black

Association

  • About VTA
  • Priorities
  • Governance
  • FAQ
  • News

Resources

  • Reports
  • Action Center
  • Economic Impact
  • Additional Resources

Action

  • Become A Member
  • Action Center
  • Subscribe to VTA Insider
  • Vaping Impact
  • Contact

Let’s Connect

Loading

Subscribe to VTA

Loading

Myth vs Fact

Continue to VTA